Defibrotide: meta-analysis of COVID-19 studies

All studies   Mortality   ICU   Hospitalization   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 150 patientsc19early.org

Defibrotide for COVID-19

Serious outcome risk
Defibrotide
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−23%
Mortality (1)−23%
ICU admission (1)0%
Hospitalization (1)−18%
RCTs (1)−23%
Late (1)−23%
00.511.5+
← Defibrotide
reduces riskIncreased
risk →
c19early.org
October 2026

Defibrotide COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jara Rubio (DB RCT)−23%1.23 · 0.66–2.27death27/10011/50
Late treatment−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →
c19early.org
October 2026

Defibrotide COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Jara Rubio (DB RCT)−23%1.23 · 0.66–2.2727/10011/50
Late treatment−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →
c19early.org
October 2026

Defibrotide COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Jara Rubio (DB RCT)0%1.00 · 0.81–1.2472/10036/50
Late treatment0%1.00 · 0.81–1.2472/10036/500% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.81–1.2472/10036/500% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →
c19early.org
October 2026

Defibrotide COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jara Rubio (DB RCT)−18%1.18 · 0.80–1.74hosp. time74 (n)39 (n)
Late treatment−18%1.18 · 0.80–1.7474 (n)39 (n)18% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.41
All studies−18%1.18 · 0.80–1.7474 (n)39 (n)18% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4100.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →
c19early.org
October 2026

Defibrotide COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jara Rubio (DB RCT)−23%1.23 · 0.66–2.27death27/10011/50
Late treatment−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →
c19early.org
October 2026

Defibrotide COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jara Rubio (DB RCT)−33%1.33 · 0.95–1.88recov. time100 (n)50 (n)
Late treatment−33%1.33 · 0.95–1.88100 (n)50 (n)33% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1
All studies−33%1.33 · 0.95–1.88100 (n)50 (n)33% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.100.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →
c19early.org
October 2026

Defibrotide COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jara Rubio (DB RCT)−23%1.23 · 0.66–2.27death27/10011/50
Late treatment−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →
c19early.org
October 2026

Defibrotide COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Jara Rubio (DB RCT)−23%1.23 · 0.66–2.2727/10011/50
Late treatment−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →
c19early.org
October 2026

Defibrotide COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jara Rubio (DB RCT)−23%1.23 · 0.66–2.27death27/10011/50
Late treatment−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.52
All studies−23%1.23 · 0.66–2.2727/10011/5023% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5200.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →
c19early.org
October 2026

Defibrotide COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jara Rubio (DB RCT)−23%1.23 · 0.66–2.27death27/10011/50 Jara Rubio (DB RCT)−5%1.05 · 0.55–1.97death23/10011/50 Jara Rubio (DB RCT)−200%3.00 · 0.70–12.89progression12/1002/50 Jara Rubio (DB RCT)0%1.00 · 0.81–1.24ICU72/10036/50 Jara Rubio (DB RCT)−18%1.18 · 0.80–1.74hosp. time74 (n)39 (n) Jara Rubio (DB RCT)−33%1.33 · 0.95–1.88recov. time100 (n)50 (n) Jara Rubio (DB RCT)−33%1.33 · 0.37–4.81misc.8/1003/50 Jara Rubio (DB RCT)6%0.94 · 0.60–1.50misc.34/10018/50
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Defibrotide
reduces riskDefibrotide
increases risk →